Zions Bancorporation National Association UT purchased a new stake in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 93,709 shares of the company's stock, valued at approximately $1,914,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Bessemer Group Inc. lifted its holdings in Stevanato Group by 14,623.3% during the 1st quarter. Bessemer Group Inc. now owns 13,251 shares of the company's stock valued at $270,000 after purchasing an additional 13,161 shares during the last quarter. Palisade Capital Management LP raised its stake in shares of Stevanato Group by 52.0% in the first quarter. Palisade Capital Management LP now owns 91,431 shares of the company's stock worth $1,867,000 after acquiring an additional 31,283 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new position in shares of Stevanato Group in the fourth quarter worth about $281,000. Envestnet Asset Management Inc. raised its stake in shares of Stevanato Group by 16.9% in the first quarter. Envestnet Asset Management Inc. now owns 162,770 shares of the company's stock worth $3,324,000 after acquiring an additional 23,545 shares during the last quarter. Finally, Yarbrough Capital LLC bought a new position in shares of Stevanato Group in the first quarter worth about $329,000.
Stevanato Group Trading Down 0.5%
Shares of STVN traded down €0.10 ($0.12) on Tuesday, reaching €21.75 ($25.29). 380,124 shares of the company's stock were exchanged, compared to its average volume of 341,708. The company has a current ratio of 1.79, a quick ratio of 1.22 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $6.59 billion, a P/E ratio of 40.28, a price-to-earnings-growth ratio of 2.23 and a beta of 0.55. The business has a 50 day moving average price of €24.52 and a two-hundred day moving average price of €22.45. Stevanato Group S.p.A. has a 12 month low of €17.12 ($19.91) and a 12 month high of €28.00 ($32.56).
Analysts Set New Price Targets
STVN has been the subject of a number of research analyst reports. Stephens raised shares of Stevanato Group to a "strong-buy" rating in a research note on Monday, April 21st. William Blair reaffirmed an "outperform" rating on shares of Stevanato Group in a research note on Monday, June 30th. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of €25.13 ($29.22).
View Our Latest Report on STVN
Stevanato Group Profile
(
Free Report)
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
See Also

Before you consider Stevanato Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stevanato Group wasn't on the list.
While Stevanato Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.